(Q36211945)

12 August 2017

1 reference

title

The benefits and risks of hormone replacement therapy: an epidemiologic overview (English)

1 reference

12 August 2017

The benefits and risks of hormone replacement therapy: An epidemiologic overview (English)

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Hormone Replacement Therapy

14 October 2022

main subject

1 reference

S. Harlap

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1605289

14 October 2022

language of work or name

English

0 references

publication date

1 June 1992

1 reference

full work available at URL

12 August 2017

https://api.elsevier.com/content/article/PII:000293789291399U?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

https://api.elsevier.com/content/article/PII:000293789291399U?httpAccept=text/plain

14 October 2022

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

American Journal of Obstetrics and Gynecology

14 October 2022

published in

1 reference

12 August 2017

volume

166

1 reference

12 August 2017

issue

6 Pt 2

1 reference

12 August 2017

page(s)

1986-1992

1 reference

The incidence and severity of atherosclerosis in estrogen-treated males, and in females with a hypoestrogenic or a hyperestrogenic state

12 August 2017

cites work

3

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Association of Exogenous Estrogen and Endometrial Carcinoma

14 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens

14 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal Endometrium

14 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Benefits and risks of menopausal estrogen and/or progestin hormone use.

14 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

14 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study

14 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Use of replacement estrogens and the risk of myocardial infarction.

14 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study

14 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Estrogen replacement therapy and protection from acute myocardial infarction

14 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community

14 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study

14 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Oestrogen replacement therapy and cardiovascular disease in post-menopausal women. A review

14 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Estrogen use and cardiovascular disease.

14 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

14 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

14 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

High density lipoproteins and atherosclerosis

14 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

14 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Survival among women with endometrial cancer: a comparison of estrogen users and nonusers

14 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Oestrogen use and survival in endometrial cancer

14 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Prevention of endometrial cancer with progestogens

14 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study

14 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Risks of estrogens and progestogens

14 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Breast cancer epidemiology

14 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Do hormones cause breast cancer?

14 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Oestrogen therapy after the menopause--boon or bane?

14 October 2022

41

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer

14 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

The risk of breast cancer after estrogen and estrogen-progestin replacement

14 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark.

14 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists

14 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Perimenopausal women's views on taking hormone replacement therapy to prevent osteoporosis

14 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Menopausal oestrogens and breast cancer risk: an expanded case-control study

14 October 2022

48

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy.

14 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Stroke prevention and oestrogen replacement therapy

14 October 2022

50

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

Long-term consequences of estrogen and estrogen-progestin replacement

14 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91399-U

14 October 2022

Identifiers

1 reference

12 August 2017

1 reference